Vedolizumab 300 MG Injection [Entyvio]
24-080
Phase 2 small_molecule active
Quick answer
Vedolizumab 300 MG Injection [Entyvio] for Immune Checkpoint Inhibitor-Related Colitis is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Immune Checkpoint Inhibitor-Related Colitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active